Current and Emerging Targets in Immunotherapy for Osteosarcoma

被引:84
|
作者
Miwa, Shinji [1 ]
Shirai, Toshiharu [1 ,2 ]
Yamamoto, Norio [1 ]
Hayashi, Katsuhiro [1 ]
Takeuchi, Akihiko [1 ]
Igarashi, Kentaro [1 ]
Tsuchiya, Hiroyuki [1 ]
机构
[1] Kanazawa Univ, Sch Med, Dept Orthopaed Surg, Kanazawa, Ishikawa 9208640, Japan
[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kyoto 6028566, Japan
关键词
SOFT-TISSUE SARCOMA; LIPOSOMAL MURAMYL TRIPEPTIDE; AUTOLOGOUS TUMOR LYSATE; HIGH-GRADE OSTEOSARCOMA; PULSED DENDRITIC CELLS; DEATH LIGAND 1; T-CELLS; INTRAVENOUS-INJECTION; MONOCYTE ACTIVATION; REFRACTORY BONE;
D O I
10.1155/2019/7035045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Emerging targets in cancer immunotherapy
    Burugu, Samantha
    Dancsok, Amanda R.
    Nielsen, Torsten O.
    SEMINARS IN CANCER BIOLOGY, 2018, 52 : 39 - 52
  • [2] Is there a role of immunotherapy in the current management of osteosarcoma?
    Smeland, S
    Bruland, O
    Jakobson, Å
    Strander, H
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 37 - 38
  • [3] Immunotherapy Targets Emerging Infectious Diseases
    Liszewski K.
    Genetic Engineering and Biotechnology News, 2019, 39 (07): : 28 - 31
  • [4] Emerging immunotherapy targets in lung cancer
    Zhu Hao-Hua
    Feng Yu
    Hu Xing-Sheng
    中华医学杂志英文版, 2020, 133 (20) : 2456 - 2465
  • [5] Emerging Targets of Immunotherapy in Gynecologic Cancer
    Cheng, Hongyan
    Zong, Liju
    Kong, Yujia
    Gu, Yu
    Yang, Junjun
    Xiang, Yang
    ONCOTARGETS AND THERAPY, 2020, 13 : 11869 - 11882
  • [6] Emerging immunotherapy targets in lung cancer
    Zhu, Hao-Hua
    Feng, Yu
    Hu, Xing-Sheng
    CHINESE MEDICAL JOURNAL, 2020, 133 (20) : 2456 - 2465
  • [7] Current and Emerging Perspectives on Immunotherapy for Melanoma
    Daud, Adil
    SEMINARS IN ONCOLOGY, 2015, 42 (06) : S3 - S11
  • [8] Osteosarcoma:: Current status of immunotherapy and future trends (Review)
    Mori, K
    Rédini, F
    Gouin, F
    Cherrier, B
    Heymann, D
    ONCOLOGY REPORTS, 2006, 15 (03) : 693 - 700
  • [9] Current and emerging therapeutic targets for IBD
    Neurath, Markus F.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (05) : 269 - 278
  • [10] Obesity: Current Therapy and Emerging Targets
    Kumar, Kashaw Sushil
    Varsha, Jatav
    Neeraj, Gupta
    Vivek, Gupta
    Rupsee, Jain
    Harish, Rajak
    Pradeep, Mishra
    INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2009, 43 (03) : 219 - 231